PrintCANCER
Stemming a Crisis in Cancer Clinical Trials
Podcast: April 26, 2010The Burrill Report (April 26, 2010): Stemming a Crisis in Cancer Clinical Trials (.MP3,14.51 Mb)
The National Cancer Institute’s Clinical Trials Cooperative Group Program involves more than 3,100 institutions and 14,000 investigators who enroll more than 25,000 patients in clinical trials each year. But a new report from the Institute of Medicine finds the program is at a critical juncture as it has grown into a complex, cumbersome, and inefficient system. We spoke to John Mendelsohn, president of the University of Texas M.D. Anderson Cancer Center and chair of the Institute of Medicine committee that wrote the report. We discussed the crisis in cancer clinical trials, the challenges the group faces, and what needs to be done to accelerate the translation of new discoveries into therapies that benefit patients with cancer.
[Please login to post comments]
- Drug Demand Remains Robust
Despite rise of generics, global pharmaceutical sales to grow to reach $1.1 trillion by 2014. Read More - Shining a Light on FDA Advisors
The agency’s proposed guidance would expand disclosure, transparency in conflict of interest waivers, agency says. Read More - Done Deals
Three life sciences companies complete their initial public offerings. Read More - An Obesity Gene's Hidden Danger
A gene variant carried by more than a third of the U.S. population could lead to brain tissue loss. Read More - Elan Renews Spinoff Hopes
Irish drugmaker considered creating two separate, publicly traded companies. Read More - Another Hit to Genzyme
The FDA proposes a $175 million settlement with the company over contaminated plant. Read More - Boehringer looks for fresh inspiration
German drugmaker looks to build profits in the face of competition from generics. Read More - FDA Tells Pfizer It Failed To Properly Monitor Trial of Antipsychotic in Kids
The weekly round-up of failed trials, missed targets and other business mishaps. Read More - Three Life Sciences Companies Go Public
A busy week for small company financings Read More - Healthcare Reform Delivers a Bonanza for Biotechs
Podcast: April 19, 2010 Read More
.gif)
- Supreme Court questions ban of biotech alfalfa
Associated Press - For $520 Million, AstraZeneca Settles Case Over Marketing of a D
The New York Times - The Search for Genes Leads to Unexpected Places
The New York Times - Drugmakers’ Overhaul Costs $105 Billion, Leerink Says
Bloomberg - Merck Revenue Cut by $170 Million From Health Law
Bloomberg - Havasupai Case Highlights Risks in DNA Research
The New York Times - Indian Tribe Wins Fight to Limit Research of Its DNA
The New York Times - Vatican to finance adult stem cell research
Associated Press - Cancer Fight: Unclear Tests for New Drug
The New York Times - Drug Sales May Advance to $1.1 Trillion on Emerging-Market Boom
Bloomberg